CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability …
[Read more...] about Akari Therapeutics Announces Launch of CEO Corner Platform
Akari Therapeutics Announces $2.5Million Registered Direct Offering
BOSTON and LONDON – October 15, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company …
[Read more...] about Akari Therapeutics Announces $2.5Million Registered Direct Offering
Akari Therapeutics Files Two NewPatents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
BOSTON and LONDON – October 9, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
BOSTON and LONDON – October 3, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate …
